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Selective naïve T cell depletion of 
allogeneic peripheral blood stem cells 
(PBSC). The results of the first clinical 
trial of naïve T cell depletion in HLA-
matched HCT showed: a) a lower rate 
of chronic GVHD compared to T cell 
replete HCT; b) the same frequency of 
acute GVHD as from standard 
treatment, although universally 
corticosteroid-sensitive; and c) 
improved immune reconstitution 
compared with complete T cell 
depletion. 
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Leukemia and other hematologic malignancies may be cured through allogeneic hematopoietic stem 
cell transplantation (HCT), in which donor cells not only support the patients' healthy blood cell 
production, but also aid their immune defense in specifically recognizing and attacking malignant 
cells, the "graft-versus-leukemia effect." However, there is a fly in the ointment in the form of graft-
versus-host disease (GVHD), signified by donor cells attacking also the recipients' healthy cells - a 
major cause of illness, disability, and even death after transplantation. Despite preventive 
medication, 30 to 70% of HLA-matched recipients develop acute GVHD, and 40 to 63% develop 
chronic GVHD. 
Strategies to overcome GVHD without compromising the graft-versus-leukemia effect have been 
pursued by researchers for many years, but advances were reported by a Fred Hutch team in the 
July issue of The Journal of Clinical Investigation. Drs. Marie Bleakley, Shelly Heimfeld, and Stanley 
Riddell from the Clinical Research Division developed a first-in-human trial of naïve T cell (TN)-
depleted stem cell grafts, in collaboration with Dr. Warren Shlomchik at the University of Pittsburgh. 
Following standard conditioning with external total body irradiation and chemotherapy, 35 high-risk 
leukemia patients were transplanted with allogeneic peripheral blood stem cell grafts that lacked TN. 
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The issue with naïve T cells in the context of transplantation is that subsets of T cells are specialized 
for different tasks, depending on their activation. TN can respond to pathogens that the immune 
system has not been exposed to previously, with the purpose of initiating an immune response. 
Some then transform into long-lived memory T cells (TM) ensuring that the body remembers how to 
deal with the foreign invaders, should they reappear. The challenge for the researchers was to find a 
strategy for separating the beneficial tumor-attacking functions of transplanted T cells from the 
adverse self-attacking properties that result from release into a new environment. Mouse studies had 
shown that TN were associated with severe GVHD, and that the effect was much less likely caused 
by TM. In addition, TM evidently transferred the valuable graft-versus-leukemia effect and acquired 
"antigen experience" to the new host. In a set of in vitro experiments, Dr. Bleakley found analogous 
results in the human setting; the human TN population comprised significantly more GVHD-triggering 
T cells than the TM population, supporting the hypothesis. A new graft-engineering strategy was 
subsequently developed using immunomagnetic beads that selectively bound CD45RA, an antigen 
that is expressed by all TN but absent in most TM (Bleakley et al. 2014). In 2009, they were ready to 
start the first clinical trial. 
The TN-depleted transplants engrafted in all 35 patients, and the overall two-year survival was 78%. 
Chronic GVHD occurred in only 9% (median follow-up 932 days) - an extraordinarily small fraction. 
Although the rate of acute GVHD was unchanged, those who developed the condition responded 
much better to anti-GVHD corticosteroid treatment compared with T cell replete recipients. Graft TM 
initiated quick recovery of T cells and transferred protective immunity, as anticipated.  
The study demonstrated that TN are key players in GVHD pathogenesis. "If you take the naïve T 
cells out of a stem cell graft you alter the natural history of GVHD essentially leading to a milder, 
consistently treatment-responsive form of acute GVHD that rarely progresses to classic chronic 
GVHD," Dr. Bleakley explained. The data also provide compelling proof-of-concept of the novel 
graft-engineering technique. "It is possible to engineer allogeneic hematopoietic stem cell grafts and 
achieve a reduction of GVHD without compromising immune reconstitution and increasing the rate of 
opportunistic infections," said Dr. Bleakley, who is currently enrolling patients for two clinical tr ials 
with TN-depleted HCT at Fred Hutch. In the first of the two, eight children with acute leukemia have 
been treated so far and are doing well; twelve remain until completion of the study. In the second 
trial 80 adult patients with immunologically compatible ("HLA-matched") unrelated donors will be 
treated, including a lower-intensity conditioning arm enabling enrollment also of older patients and 
patients who are less fit for transplantation due to other medical conditions. 
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There is still plenty to learn, however, both regarding optimization of TN-depleted transplantation and 
regarding the biology of the observed (mild) acute GVHD. Furthermore, little is known about any 
potential long-term effects on the immune system from this technique. Dr. Bleakley concluded, "if we 
continue to observe positive outcomes with a very low rate of chronic GVHD and good immune 
reconstitution we will plan larger trials with other centers in addition to the hutch and University of 
Pittsburgh, and possibly randomized controlled trials." 
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